Citation: Mei Haibo, Márió Remete Attila, Zou Yupiao, Moriwaki Hiroki, Fustero Santos, Kiss Lorand, Soloshonok Vadim A., Han Jianlin. Fluorine-containing drugs approved by the FDA in 2019[J]. Chinese Chemical Letters, ;2020, 31(9): 2401-2413. doi: 10.1016/j.cclet.2020.03.050 shu

Fluorine-containing drugs approved by the FDA in 2019

a.
Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China
b.
University of Szeged, Institute of Pharmaceutical Chemistry, 6720 Szeged, Eötvös u. 6, Hungary
c.
Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka 533-0024, Japan
d.
Departamento de Química Orgánica, Universidad de Valencia, 46100 Burjassot, Valencia, Spain
e.
Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018 San Sebastián, Spain
f.
IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, Plaza Bizkaia, 48013 Bilbao, Spain

Author Bio: Haibo Mei obtained his B.Sc. in 2009 and Ph.D. in 2014 in organic chemistry from Nanjing University. Then he joined Nanjing University as a research fellow in the area of asymmetric synthesis. In 2018, he moved to Nanjing Forestry University and became an associate professor there. His research interests focus on organic fluorine chemistry, electrochemical synthesis and asymmetric synthesis
Attila Márió Remete graduated as chemist in 2014 from University of Szeged, Faculty of Science and Informatics. He received his Ph.D. degree at the Institute of Pharmaceutical Chemistry, University of Szeged under the supervision of Prof. Dr. Loránd Kiss in 2019. Since 2018, he is an assistant lecturer at the University of Szeged. His research interests include β-amino acids, fluorine incorporation and selective functionalizations
Yupiao Zou obtained her B.Sc. in 2018 from Wuhan Institute of Technology. She is currently undergraduate student in the research group of Professor Han at Nanjing Forestry University. Her research focuses on fluorine chemistry
Hiroki Moriwaki, Ph.D graduated from Kyoto Pharmaceutical University in 1985. Then he joined the Technical section at Manufacturing Department of Hamari Chemicals, Ltd. In 2006 he has been working as a Director, Research & Development Department at Hamari Chemicals, Ltd. From 2010 to 2011 he joined the Institute for Chemical Biology and Drug Discovery (ICB & DD) at Stony Brook University, and has been working to develop a new methodology for the synthesis of tailor-made amino acids derivatives. His specialty is development of a practical synthetic method of the special amino acid and peptide. From 2015, he is a board member of Hamari Chemicals, Ltd. In addition, He is currently serving as a councilor of the Japan peptide Society
Santos Fustero studied chemistry at the University of Zaragoza, where he obtained his bachelor's degree in 1972. He received his Ph.D. in organic chemistry in 1975 from the same university under the supervision of Profs. Barluenga and Gotor. He carried out postdoctoral studies for two years at Prof. Lehmkuhl's group at the MaxPlanck-Institut für Kohlenforschung in Mülheim/Ruhr, Germany. In 1983, he became an associate professor at the University of Oviedo, and in 1990, he was promoted to a full professor at the University of Valencia. His research interests include organofluorine and medicinal chemistry, organocatalysis, heterocyclic chemistry and new reaction methodologies
Loránd Kiss completed his Ph.D. in 2002 in the Department of Organic Chemistry at the Faculty of Sciences, Debrecen University (Debrecen, Hungary) under the supervision of Prof. Sándor Antus. In 2003, he joined the research team of Professor Ferenc Fülöp at the Institute of Pharmaceutical Chemistry, University of Szeged (Szeged, Hungary), where he started to work in the area of cyclic β-amino acid chemistry. He followed postdoctoral research in the laboratories of Prof. Norbert De Kimpe at Ghent University (Ghent, Belgium), and Prof. Santos Fustero, University of Valencia. He is currently professor and head of department at the Institute of Pharmaceutical Chemistry, University of Szeged. His scientific interest is directed towards the selective functionalization β-amino acid derivatives and on the synthesis of highly functionalized fluorinated building blocks
Vadim A. Soloshonok graduated from Kiev State University in 1983 and received his Ph.D. in 1987 from the Ukrainian Academy of Sciences. He is the Ikerbasque Research Professor at the University of Basque Country, San Sebastian, Spain. He is currently serving as a member of the advisory editorial board of the Journal of Fluorine Chemistry, Synthesis Editor of Amino Acids, Editor-inChief of Organic Section of Molecules, Past-Chair of the ACS Fluorine Division; author of 350+ research papers. His current research interests are fluorine chemistry, asymmetric synthesis, self-disproportionation of enantiomers
Jianlin Han received his Ph.D. in organic Chemistry in 2007 from Nanjing University. He then carried out postdoctoral studies for one year at Texas Tech University. In 2008, he moved to the University of Oklahoma to continue postdoctoral research for nearly one year. In 2009 he took the position of Associate Professor at the Nanjing University. In 2019, he moved to Nanjing Forestry University and became a professor there. His research topics include organic fluorine chemistry, amino acids, radical reaction, and asymmetric synthesis

^**

kiss.lorand@pharm.u-szeged.hu

vadym.soloshonok@ehu.es

hanjl@njfu.edu.cn

Received Date: 6 February 2020
Revised Date: 8 March 2020
Accepted Date: 18 March 2020
Available Online: 19 March 2020

Figures(30)

Eleven new fluorine-containing FDA-approved drugs have been profiled and details of their discovery and preparation are discussed. Therapeutic areas include schizophrenia, migraine, multiple sclerosis, insomnia, rheumatoid arthritis, anti-tuberculosis, breast cancer, lymphoma kinase inhibitor, serotonin receptor antagonist. New pharmaceuticals feature four examples of aromatic fluorine, three aromatic CF₃ group, three aliphatic CF₃ and one compound with aromatic CF₃O group. Furthermore, among the new compounds, six are chiral and seven are derived from tailor-made amino acids.
- Fluorine,
- Pharmaceuticals,
- Synthesis,
- Medicinal chemistry,
- Marketed medicinal drugs
1. [1]
  (a) J. Fried, E.F. Sabo, J. Am. Chem. Soc. 75 (1953) 2273-2274;
  (b) J. Fried, E.F. Sabo, J. Am. Chem. Soc. 76 (1954) 1455-1456.
2. [2]
  (a) C. Heidelberger, N.K. Chaudhuri, P. Danneberg, et al., Nature 179 (1957) 663-666;
  (b) D.B. Longley, D.P. Harkin, P.G. Johnston, Nat. Rev. Cancer 3 (2003) 330-338.
3. [3]
  D. O'Hagan, J. Fluorine Chem. 131 (2010) 1071-1081. doi: 10.1016/j.jfluchem.2010.03.003
4. [4]
  J.A. Tobert, Nat. Rev. Drug Discov. 2 (2003) 517-526. doi: 10.1038/nrd1112
5. [5]
  (a) Q.A. Huchet, B. Kuhn, B. Wagner, et al., J. Med. Chem. 58 (2015) 9041-9060;
  (b) B. Jeffries, Z. Wang, H.R. Felstead, et al., J. Med. Chem. 63 (2020) 1002-1031;
  (c) A.D. Wade, A. Rizzi, Y. Wang, D.J. Huggins, J. Chem. Inf. Model. 59 (2019) 2776-2784;
  (d) E.N.G. Marsh, Acc. Chem. Res. 47 (2014) 2878-2886;
  (e) A.A. Berger, J.S. Völler, N. Budisa, B. Koksch, Acc. Chem. Res. 50 (2017) 2093-2103;
  (f) L. Kiss, A.M. Remete, Eur. J. Org. Chem. (2019) 5574-5602;
  (g) L. Kiss, F. Fülöp, Chem. Rec. (2018) 266-281;
  (h) A.M. Remete, M. Nonn, S. Fustero, F. Fülöp, L. Kiss, Tetrahedron 74 (2018) 6367-6418;
  (i) M. Nonn, L. Kiss, M. Haukka, S. Fustero, F. Fülöp, Org. Lett. 17 (2015) 1074-1077;
  (j) J. Liu, Z. Li, H. Mei, V.A. Soloshonok, J.L. Han, ACS Omega 4 (2019) 19505-19512;
  (k) C. Xie, L. Zhang, W. Sha, et al., Org. Lett. 18 (2016) 3270-3273;
  (l) X. Xu, X. Dong, Z. Zhang, et al., Macroheterocycles 12 (2019) 403-408.
6. [6]
  (a) J. Wang, M. Sánchez-Roselló, J.L. Aceña, et al., Chem. Rev. 114 (2014) 2432-2506;
  (b) Y. Zhou, J. Wang, Z. Gu, S. Wang, W. Zhu, J.L. Aceña, V.A. Soloshonok, K. Izawa, H. Liu, Chem. Rev. 116 (2016) 422-518;
  (c) W. Zhu, J. Wang, S. Wang, et al., J. Fluorine Chem. 167 (2014) 37-54;
  (d) Y. Zhu, J.L. Han, J. Wang, et al., Chem. Rev. 118 (2018) 3887-3964;
  (e) H. Mei, J. Han, K.D. Klika, et al., Eur. J. Med. Chem. 186 (2020) 111826;
  (f) N.A. Meanwell, J. Med. Chem. 61 (2018) 5822-5880.
7. [7]
  H. Mei, J. Han, S. Fustero, et al., Chem. Eur. J. 25 (2019) 11797-11819. doi: 10.1002/chem.201901840
8. [8]
  H.A. Blair, Drugs 80 (2020) 417-423. doi: 10.1007/s40265-020-01271-6
9. [9]
  A.J. Robichaud, T. Lee, W. Deng, et al., PCT/US2000/016498, 2000.
10. [10]
  T. Lee, A.J. Robichaud, K.E. Boyle, et al., Bioorg. Med. Chem. Lett. 13 (2003) 767-770. doi: 10.1016/S0960-894X(02)01028-4
11. [11]
  P. Li, Q. Zhang, A.J. Robichaud, et al., J. Med. Chem. 57 (2014) 2670-2682. doi: 10.1021/jm401958n
12. [12]
  R.E. Davis, C.U. Correll, Expert Rev. Neurother. 16 (2016) 601-614. doi: 10.1080/14737175.2016.1174577
13. [13]
  N. Zisapel, Expert Opin, Investig. Drugs 24 (2014) 401-411.
14. [14]
  J.A. Lieberman, R.E. Davis, C.U. Correll, et al., Biol. Psychiatry 79 (2016) 952-961. doi: 10.1016/j.biopsych.2015.08.026
15. [15]
  K.E. Vanover, R.E. Davis, Y. Zhou, et al., Neuropsychopharmacology 44 (2019) 598-605. doi: 10.1038/s41386-018-0251-1
16. [16]
  F. Carponi, C. Fabbri, I. Bitter, et al., Eur. Neuropsychopharmacol. 29 (2019) 971-985. doi: 10.1016/j.euroneuro.2019.06.008
17. [17]
  I.M. Bell, M.E. Fraley, S.N. Gallicchio, et al., US2010/0122899, 2012.
18. [18]
  P.R. Holland, P.J. Goadsby, Neurotherapeutics 15 (2018) 304-312. doi: 10.1007/s13311-018-0617-4
19. [19]
  P. Martelletti, M.A. Giamberardino, Expert Opin. Pharmacol. 20 (2018) 209-218.
20. [20]
  R.B. Lipton, D.W. Dodick, J. Ailani, et al., JAMA 322 (2019) 1887-1898. doi: 10.1001/jama.2019.16711
21. [21]
  I.M. Bell, M.E. Fraley, S.N. Gallicchio, et al., PCT/US2011/060081, 2012.
22. [22]
  F. Chen, C. Molinaro, W.P. Wuelfing, et al., PCT/US2013/030692, 2013.
23. [23]
  K.M. Belyk, E. Cleator, S.C. Kuo, et al., PCT/US2013/030696, 2013.
24. [24]
  N. Yasuda, E. Cleator, B. Kosjek, et al., Org. Process Res. Dev. 21 (2017) 1851-1858. doi: 10.1021/acs.oprd.7b00293
25. [25]
  P. Gergely, B. Nuesslein-Hildesheim, D. Guerini, et al., Brit. J. Pharmacol. 167 (2012) 1035-1047. doi: 10.1111/j.1476-5381.2012.02061.x
26. [26]
  S. Pan, N.S. Gray, W. Gao, et al., ACS Med. Chem. Lett. 4 (2013) 333-337. doi: 10.1021/ml300396r
27. [27]
  E. Legangneux, A. Gardin, D. Johns, Br. J. Clin. Pharmacol. 75 (2012) 831-841.
28. [28]
  K. Selmaj, D.K.B. Li, H.P. Hartung, et al., Lancet Neurol. 12 (2013) 756-767. doi: 10.1016/S1474-4422(13)70102-9
29. [29]
  R.M. Fryer, A. Muthukumarana, P.C. Harrison, et al., PLoS One 7 (2012) e52985. doi: 10.1371/journal.pone.0052985
30. [30]
  Z.T. Al-Salama, Drugs 79 (2019) 1009-1015. doi: 10.1007/s40265-019-01140-x
31. [31]
  L. Kappos, A. Bar-Or, B.A.C. Cree, Lancet 391 (2018) 1263-1273. doi: 10.1016/S0140-6736(18)30475-6
32. [32]
  U. Glaenzel, Y. Jin, R. Nufer, et al., Drug Metab. Dispos. 46 (2018) 1001-1013. doi: 10.1124/dmd.117.079574
33. [33]
  A. Gentile, A. Musella, S. Bullitta, et al., J. Neuroinflamm. 13 (2016) 207. doi: 10.1186/s12974-016-0686-4
34. [34]
  C. O'Sullivan, A. Schubart, A.K. Mir, K.K. Dev, J. Neuroinflamm. 13 (2016) 31. doi: 10.1186/s12974-016-0494-x
35. [35]
  R. Yamamoto, T. Aoki, H. Koseki, et al., Br. J. Pharmacol. 174 (2017) 2085-2101. doi: 10.1111/bph.13820
36. [36]
  Z. Chen, T.M. Doyle, L. Luongo, et al., PNAS 116 (2019) 10557-10562. doi: 10.1073/pnas.1820466116
37. [37]
  T. Bobinger, A. Manaenko, P. Burkardt, et al., Stroke 50 (2019) 3246-3254. doi: 10.1161/STROKEAHA.119.027134
38. [38]
  S. Pan, W. Gao, N.S. Gray, Y. Mi, Y. Fan, PCT/US2004/015603, 2004.
39. [39]
  Y. Liu, D. Papoutsakis, E. Roddy, PCT/US2009/068346, 2010.
40. [40]
  L. Ciszewski, M. de la Cruz, P.H. Karpinski, et al., PCT/US2009/068143, 2010.
41. [41]
  M. de la Cruz, P.H. Karpinski, Y. Liu, PCT/US2009/068352, 2010.
42. [42]
  F. Gallou, J.M. Sedelmeier, C. Vogel, PCT/EP2013/052106, 2013.
43. [43]
  Y. Yoshida, T. Terauchi, Y. Naoe, et al., Bioorg. Med. Chem. 22 (2014) 6071-6088. doi: 10.1016/j.bmc.2014.08.034
44. [44]
  Y. Yoshida, Y. Naoe, T. Terauchi, et al., J. Med. Chem. 58 (2015) 4648-4664. doi: 10.1021/acs.jmedchem.5b00217
45. [45]
  P.J. Murphy, S. Yasuda, K. Nakai, et al., J. Clin. Pharmacol. 57 (2017) 96-104. doi: 10.1002/jcph.785
46. [46]
  P. Murphy, M. Moline, D. Mayleben, et al., J. Clin. Sleep Med. 13 (2017) 1289-1299. doi: 10.5664/jcsm.6800
47. [47]
  R. Rosenberg, P. Murphy, G. Zammit, et al., JAMA Netw. Open 2 (2019) e1918254. doi: 10.1001/jamanetworkopen.2019.18254
48. [48]
  G.A. Moniz, A.Z. Wilcoxen, F. Benayoud, et al., PCT/US2013/026204, 2013.
49. [49]
  S. Nakayamada, S. Kubo, S. Iwata, Y. Tanaka, BioDrugs 30 (2016) 407-419. doi: 10.1007/s40259-016-0190-5
50. [50]
  M.E.F. Mohamed, H.S. Camp, P. Jiang, et al., Clin. Pharmacokinet. 55 (2016) 1547-1558. doi: 10.1007/s40262-016-0419-y
51. [51]
  N. Wishart, M.A. Argiriadi, D.J. Calderwood, et al., WO2011068881, 2011.
52. [52]
  (a) G.R. Burmester, J.M. Kremer, F. Van den Bosch, et al., Lancet 391 (2018) 2503-2512;
  (b) M.C. Genovese, R. Fleischmann, B. Combe, et al., Lancet 391 (2018) 2513-2524.
53. [53]
  J.S. Smolen, A.L. Pangan, P. Emery, et al., Lancet 393 (2019) 2303-2311. doi: 10.1016/S0140-6736(19)30419-2
54. [54]
  R. Fleischmann, A.L. Pangan, I.H. Song, et al., Arthritis Rheumatol. 71 (2019) 1788-1800. doi: 10.1002/art.41032
55. [55]
  F. D'Amico, G. Fiorino, F. Furfaro, M. Allocca, S. Danese, Expert Opin. Invest. Drugs 27 (2018) 595-599. doi: 10.1080/13543784.2018.1492547
56. [56]
  T. Perez-Jeldres, C.J. Tyler, J.D. Boyer, et al., Front. Pharmacol. 10 (2019) 212. doi: 10.3389/fphar.2019.00212
57. [57]
  R. Panaccione, G.R. D'Haens, W.J. Sandborn, et al., Gastroenterology 156 (2019) S-170.
58. [58]
  E. Guttman-Yassky, D. Thaçi, A.L. Pangan, et al., J. Allergy Clin. Immunol. (2019) 145 (2020) 877-884. doi: 10.1016/j.jaci.2019.11.025
59. [59]
  N. Wishart, M.A. Argiriadi, D.J. Calderwood, PCT/US2010/058572, 2011.
60. [60]
  J.W. Voss, H.S. Camp, R.J. Padley, PCT/US2014/062145, 2015.
61. [61]
  (a)V.A. Soloshonok, H. Ohkura, K.Uneyama, Tetrahedron Lett. 43 (2002) 5449-5452;
  (b) V.A. Soloshonok, T. Ono, I.V. Soloshonok, J. Org. Chem. 62 (1997) 7538-7539;
  (c) V.A. Soloshonok, V.P. Kukhar, Tetrahedron 52 (1996) 6953-6964.
62. [62]
  A. Allian, J. Jayanth, M.E. Mohamed, et al., PCT/US2016/057372, 2017.
63. [63]
  S. Oruganti, B. Kandagatla, S. Sen, et al., PCT/IB2018/055368, 2019.
64. [64]
  R. Singh, U. Manjunatha, H.I.M. Boshoff, et al., Science 322 (2008) 1392-1395. doi: 10.1126/science.1164571
65. [65]
  S. Patterson, S. Wyllie, L. Stojanovski, et al., Antimicrob. Agents Chemother. 57 (2013) 4699-4706. doi: 10.1128/AAC.00722-13
66. [66]
  (a) M.A. Marsini, P.J. Reider, E.J. Sorensen, J. Org. Chem. 75 (2010) 7479-7482;
  (b) G.C. Moraski, A.G. Oliver, L.D. Markley, et al., Bioorg. Med. Chem. Lett. 24 (2014) 3493-3498.
67. [67]
  S.J. Keam, Drug 79 (2019) 1797-1803. doi: 10.1007/s40265-019-01207-9
68. [68]
  W.R. Baker, C. Shaopei, E.L. Keeler, US 6087358, 2000.
69. [69]
  P. Furet, V. Guagnano, R.A. Fairhurst, et al., Bioorg. Med. Chem. Lett. 23 (2013) 3741-3748. doi: 10.1016/j.bmcl.2013.05.007
70. [70]
  M. Gerspacher, R.A. Fairhurst, R. Mah, et al., Bioorg. Med. Chem. Lett. 25 (2015) 3582-3584. doi: 10.1016/j.bmcl.2015.06.077
71. [71]
  F. André, E. Ciruelos, G. Rubovszky, et al., N. Engl. J. Med. 380 (2019) 1929-1940. doi: 10.1056/NEJMoa1813904
72. [72]
  A. Markham, Drugs 79 (2019) 1249-1253. doi: 10.1007/s40265-019-01161-6
73. [73]
  (a) V.P. Sandanayaka, S. Shacham, D. Mccauley, S. Shechter, WO2013019548, 2013;
  (b) M. Garg, D. Kanojia, A. Mayakonda, et al., Oncotarget 8 (2017) 7521-7532
74. [74]
  Y.Y. Syed, Drugs 79 (2019) 1485-1494. doi: 10.1007/s40265-019-01188-9
75. [75]
  A.R. Muthusamy, S.L. Kanniah, A. Ravi, et al., WO2018129227, 2018.
76. [76]
  M. Menichincheri, E. Ardini, P. Magnaghi, et al., J. Med. Chem. 59 (2016) 3392-3408. doi: 10.1021/acs.jmedchem.6b00064
77. [77]
  D. Liu, M. Offin, S. Harnicar, B.T. Li, A. Drilon, Ther. Clin. Risk Manag. 14 (2018) 1247-1252. doi: 10.2147/TCRM.S147381
78. [78]
  R. Iyer, L. Wehrmann, R.L. Golden, et al., Cancer Lett. 372 (2016) 179-186. doi: 10.1016/j.canlet.2016.01.018
79. [79]
  G. Wei, R. Patel, C. Walsh, et al., Eur. J. Cancer 69 (2016) S33.
80. [80]
  Z.T. AI-Salama, S.J. Keam, Drugs 79 (2019) 1477-1483. doi: 10.1007/s40265-019-01177-y
81. [81]
  C. Zhang, J. Zhang, P.N. Ibrahim, et al., WO2008064255, 2008.
82. [82]
  P.N. Ibrahim, M. Jin, S. Matsuura, PCT Int. Appl. WO2016179412, 2016.
83. [83]
  Y.N. Lamb, Drugs 79 (2019) 1805-1812. doi: 10.1007/s40265-019-01210-0
84. [84]
  D. Chen, Y. Zhang, J. Li, Y. Liu, Synthesis 51 (2019) 2564-2571. doi: 10.1055/s-0037-1612421
85. [85]
  D.L. Nelson, L.A. Phebus, K.W. Johnson, et al., Cephalalgia 30 (2010) 1159-1169. doi: 10.1177/0333102410370873
86. [86]
  M.D. Ferrari, M. Färkkilä, U. Reuter, et al., Cephalalgia 30 (2010) 1170-1178. doi: 10.1177/0333102410375512
87. [87]
  Y.J. Jin, X.W. Yang, X.X. Xie, H. Tian, Y.L. Cui, Drugs Clinic 31 (2016) 1300-1303.
88. [88]
  Y.N. Lamb, Durgs 79 (2019) 1989-1996.
89. [89]
  M.P. Cohen, D.T. Kohlman, S.X. Liang, V. Mancuso, F. Victor, PCT Int. Appl. WO200384949, 2003.
90. [90]
  N.A. Meanwell, J. Med. Chem. 54 (2011) 2529-2591. doi: 10.1021/jm1013693
91. [91]
  (a) J.A. Ma, D. Cahard, J. Fluorine Chem. 128 (2007) 975-996;
  (b) A. Sato, M.V. Ponomarenko, T. Ono, G.V. Röschenthaler, V.A. Soloshonok, Eur. J. Org. Chem. 2019 (2019) 4417-4421;
  (c) H. Mei, J.L. Han, S. White, G. Butler, V.A. Soloshonok, J. Fluorine Chem. 227 (2019)109370;
  (d) C. Yang, A. Hassanpour, K. Ghorbanpour, S. Abdolmohammadi, E. Vessally, RSC Adv. 9 (2019) 27625-27639;
  (e) Z. Zhang, Adv. Synth. Catal. 359 (2017) 372-383;
  (f) S.L. Clarke, G.P. McGlacken, Chem. Eur. J. 23 (2017) 1219-1230;
  (g) Y. Ouyang, X.H. Xu, F.L. Qing, Angew. Chem. Int. Ed. 57 (2018) 6926-6929;
  (h) J. Kalim, T. Duhail, T.N. Le, et al., Chem. Sci. 10 (2019) 10516-10523.
92. [92]
  (a) J. Han, O. Kitagawa, A. Wzorek, K.D. Klika, V.A. Soloshonok, Chem. Sci. 9 (2018) 1718-1739;
  (b) M.Yasumoto, H.Ueki, V.A.Soloshonok, J.FluorineChem.131 (2010)266-269.
93. [93]
  (a) A.E. Sorochinsky, J.L. Aceña, V.A. Soloshonok, Synthesis 45 (2013) 141-152;
  (b) M. Yasumoto, H. Ueki, T. Ono, T. Katagiri, V.A. Soloshonok, J. Fluorine Chem. 131 (2010) 535-539.
94. [94]
  (a) A.E. Sorochinsky, T. Katagiri, T. Ono, et al., Chirality 25 (2013) 365-368;
  (b) T. Nakamura, K. Tateishi, S. Tsukagoshi, et al., Tetrahedron 68 (2012) 4013-4017.
95. [95]
  (a) H. Ueki, M. Yasumoto, V.A. Soloshonok, Tetrahedron Asymmetry 21 (2010) 1396-1400;
  (b) J. Han, D.J. Nelson, A.E. Sorochinsky, V.A. Soloshonok, Curr. Org. Synth. 8 (2011) 310-317.
96. [96]
  (a) C. Xie, L. Wu, J. Han, V.A. Soloshonok, Y. Pan, Angew. Chem. Int. Ed. 54 (2015) 6019-6023;
  (b) J. Han, V.A. Soloshonok, K.D. Klika, J. Drabowicz, A. Wzorek, Chem. Soc. Rev. 47 (2018) 1307-1350.
97. [97]
  (a) A. Henninot, J.C. Collins, J.M. Nuss, J. Med. Chem. 61 (2018) 1382-1414;
  (b) M.A.T. Blaskovich, J. Med. Chem. 59 (2016) 10807-10836;
  (c) D.R.W. Hodgson, J.M. Sanderson, Chem. Soc. Rev. 33 (2004) 422-430;
  (d) T. Sato, K. Izawa, J.L. Aceña, H. Liu, V.A. Soloshonok, Eur. J. Org. Chem. 2016 (2016) 2757-2774;
  (e) V.A. Soloshonok, K. Izawa, Asymmetric synthesis and application of α-amino acids, ACS Symposium Series 1009, Oxford University Press, Oxford, 2009;
  (f) S. Wang, Y. Wang, J. Wang, et al., Curr. Pharm. Des. 23 (2017) 4493-4554.
98. [98]
  (a) D. Stepec, M. Ponikvar-Svet, Acta Chim. Slovenica 66 (2019) 255-275;
  (b) D. Stepec, G. Tavccar, M. Ponikvar-Svet, Environ. Pollut. 248 (2019) 958-964;
  (c) M. Ponikvar, V. Stibilj, B. Zemva, Food Chem.103 (2007) 369-374;
  (d) A. Koblar, G. Tavcar, M. Ponikvar-Svet, Food Chem.130 (2012) 286-290.
1. [1]
  Qian Wang , Yeping Bian , Gagan Dhawan , Wei Zhang , Alexander E. Sorochinsky , Ata Makarem , Vadim A. Soloshonok , Jianlin Han . FDA approved fluorine-containing drugs in 2023. Chinese Chemical Letters, 2024, 35(11): 109780-. doi: 10.1016/j.cclet.2024.109780
2. [2]
  Jia-Ru Li , Ning Li , Li-Ling He , Jun He . Fluorine-functionalized zirconium-organic cages for efficient photocatalytic oxidation of thioanisole. Chinese Chemical Letters, 2025, 36(1): 109934-. doi: 10.1016/j.cclet.2024.109934
3. [3]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
4. [4]
  Xinhui Fang , Xinrui Wang , Bin Ding . Applications of luminescent metal-organic frameworks as pioneering biosensors for biological and chemical detection. Chinese Chemical Letters, 2025, 36(8): 110453-. doi: 10.1016/j.cclet.2024.110453
5. [5]
  Yulong Shi , Fenbei Chen , Mengyuan Wu , Xin Zhang , Runze Meng , Kun Wang , Yan Wang , Yuheng Mei , Qionglu Duan , Yinghong Li , Rongmei Gao , Yuhuan Li , Hongbin Deng , Jiandong Jiang , Yanxiang Wang , Danqing Song . Chemical construction and anti-HCoV-OC43 evaluation of novel 10,12-disubstituted aloperine derivatives as dual cofactor inhibitors of TMPRSS2 and SR-B1. Chinese Chemical Letters, 2024, 35(5): 108792-. doi: 10.1016/j.cclet.2023.108792
6. [6]
  Huiju Cao , Lei Shi . sp¹-Hybridized linear and cyclic carbon chain. Chinese Chemical Letters, 2025, 36(4): 110466-. doi: 10.1016/j.cclet.2024.110466
7. [7]
  Peng Zhan . Practice and Reflection in Training Medicinal Chemistry Graduate Students. University Chemistry, 2024, 39(6): 112-121. doi: 10.3866/PKU.DXHX202402022
8. [8]
  Xinyi Zhang , Kai Ren , Yanning Liu , Zhenyi Gu , Zhixiong Huang , Shuohang Zheng , Xiaotong Wang , Jinzhi Guo , Igor V. Zatovsky , Junming Cao , Xinglong Wu . Progress on Entropy Production Engineering for Electrochemical Catalysis. Acta Physico-Chimica Sinica, 2024, 40(7): 2307057-0. doi: 10.3866/PKU.WHXB202307057
9. [9]
  Lei Feng , Ze-Min Zhu , Ying Yang , Zongbin He , Jiafeng Zou , Man-Bo Li , Yan Zhao , Zhikun Wu . Long-Pursued Structure of Au₂₃(S-Adm)₁₆ and the Unexpected Doping Effects. Acta Physico-Chimica Sinica, 2024, 40(5): 2305029-0. doi: 10.3866/PKU.WHXB202305029
10. [10]
  Ying Chen , Ronghua Yan , Weiyan Yin . Research Progress on the Synthesis of Metal Single-Atom Catalysts and Their Applications in Electrocatalytic Hydrogen Evolution Reactions. University Chemistry, 2025, 40(9): 344-353. doi: 10.12461/PKU.DXHX202503066
11. [11]
  Jiaming Xu , Yu Xiang , Weisheng Lin , Zhiwei Miao . Research Progress in the Synthesis of Cyclic Organic Compounds Using Bimetallic Relay Catalytic Strategies. University Chemistry, 2024, 39(3): 239-257. doi: 10.3866/PKU.DXHX202309093
12. [12]
  Tengteng Wang , Yiming Ju , Yao Cheng , Haiyang Wang , Dejin Zang . Recent advances in polyoxometalates based strategies for green synthesis of drugs. Chinese Chemical Letters, 2025, 36(5): 109871-. doi: 10.1016/j.cclet.2024.109871
13. [13]
  Jie Yang , Xin-Yue Lou , Dihua Dai , Jingwei Shi , Ying-Wei Yang . Desymmetrized pillar[8]arenes: High-yield synthesis, functionalization, and host-guest chemistry. Chinese Chemical Letters, 2025, 36(1): 109818-. doi: 10.1016/j.cclet.2024.109818
14. [14]
  Haijiao Li , Mingzu Zhang , Jinlin He , Jian Liu , Xingwei Sun , Peihong Ni . Synthesis of curcumin polyprodrug via click chemistry and construction of dual-drug-loaded nano platform for highly efficient tumor treatment. Chinese Chemical Letters, 2025, 36(8): 110615-. doi: 10.1016/j.cclet.2024.110615
15. [15]
  Boran Cheng , Lei Cao , Chen Li , Fang-Yi Huo , Qian-Fang Meng , Ganglin Tong , Xuan Wu , Lin-Lin Bu , Lang Rao , Shubin Wang . Fluorine-doped carbon quantum dots with deep-red emission for hypochlorite determination and cancer cell imaging. Chinese Chemical Letters, 2024, 35(6): 108969-. doi: 10.1016/j.cclet.2023.108969
16. [16]
  Yu-Yu Tan , Lin-Heng He , Wei-Min He . Copper-mediated assembly of SO₂F group via radical fluorine-atom transfer strategy. Chinese Chemical Letters, 2024, 35(9): 109986-. doi: 10.1016/j.cclet.2024.109986
17. [17]
  Zhuangzhuang Zhang , Yaru Qiao , Jun Zhao , Dai-Huo Liu , Mengmin Jia , Hongwei Tang , Liang Wang , Dongmei Dai , Bao Li . Fluorine-doped K_0.39Mn_0.77Ni_0.23O_1.9F_0.1 microspheres with highly reversible oxygen redox reaction for potassium-ion battery cathode. Chinese Chemical Letters, 2025, 36(3): 109907-. doi: 10.1016/j.cclet.2024.109907
18. [18]
  Wei Chen , Pieter Cnudde . A minireview to ketene chemistry in zeolite catalysis. Chinese Journal of Structural Chemistry, 2024, 43(11): 100412-100412. doi: 10.1016/j.cjsc.2024.100412
19. [19]
  Huimin Luan , Qinming Wu , Jianping Wu , Xiangju Meng , Feng-Shou Xiao . Templates for the synthesis of zeolites. Chinese Journal of Structural Chemistry, 2024, 43(4): 100252-100252. doi: 10.1016/j.cjsc.2024.100252
20. [20]
  Hang Wang , Qi Wang , Chuan-De Wu . Continuous synthesis of ammonia. Chinese Journal of Structural Chemistry, 2025, 44(3): 100437-100437. doi: 10.1016/j.cjsc.2024.100437

Get Citation

PDF

XML

Metrics

PDF Downloads(72)
Abstract views(3524)
HTML views(395)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142